Sun Pharmaceutical Industries and Bayer today announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India.
Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.
Under the terms of the agreement, Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa®. Finerenone was first launched by Bayer under the brand name Kerendia TM in 2022. |